Amphastar Pharmaceuticals Inc
Company Profile
Business description
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Contact
11570 6th Street
Rancho CucamongaCA91730
USAT: +1 909 980-9484
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,028
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
stocks
Goldman Sachs Earnings: Valuations remain stretched
stocks
Major ASX listed miners overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 19.70 | -0.22% |
| CAC 40 | 8,112.02 | 146.92 | -1.78% |
| DAX 40 | 24,959.06 | 338.07 | -1.34% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,195.35 | 39.94 | -0.39% |
| HKSE | 26,618.01 | 54.11 | 0.20% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,099.54 | 484.03 | -0.90% |
| NZX 50 Index | 13,573.93 | 6.36 | -0.05% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,815.90 | 20.70 | -0.23% |
| SSE Composite Index | 4,109.96 | 4.04 | -0.10% |